HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain

HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain

The study purpose is to investigate plasma HIV-1 RNA dynamics in subjects initiating raltegravir-based salvage therapy and quantify the corresponding changes in levels of cellular HIV-1 DNA.

First- and second-phase decay rates of plasma HIV-1 RNA and changes in the intracellular levels of HIV-1 proviral DNA and LTR circles will be measured in subjects starting salvage antiretroviral therapy including raltegravir in Spain.

Inclusion Criteria:

• Patients who have limited or no treatment options due to extensive antiretroviral drug resistance or drug intolerance.
• Subjects initiating raltegravir plus another fully active antiretroviral drug.

Exclusion Criteria:

• Pregnancy, or fertile women willing to be pregnant.
• Active substance abuse or major psychiatric disease.